Mireille Ruiz1, Pénélope Labauge2, Anne Louboutin3, Olivier Limot2, Arnaud Fauconnier4, Cyrille Huchon5. 1. Department of Gynecology and Obstetrics, CHI Poissy-St-Germain, 10, rue du Champ Gaillard, 78300 Poissy, France. 2. Department of Radiology, CHI Poissy-St-Germain, 10, rue du Champ Gaillard, 78300 Poissy, France. 3. Department of Pathology, CHI Poissy-St-Germain, 10, rue du champ Gaillard, 78300 Poissy, France. 4. Department of Gynecology and Obstetrics, CHI Poissy-St-Germain, 10, rue du Champ Gaillard, 78300 Poissy, France; EA 7285 Risques Cliniques et Sécurité en Santé des Femmes, Université Versailles-Saint-Quentin-en-Yvelines, 78000 Versailles, France. 5. Department of Gynecology and Obstetrics, CHI Poissy-St-Germain, 10, rue du Champ Gaillard, 78300 Poissy, France; EA 7285 Risques Cliniques et Sécurité en Santé des Femmes, Université Versailles-Saint-Quentin-en-Yvelines, 78000 Versailles, France. Electronic address: cyrillehuchon@yahoo.fr.
Abstract
OBJECTIVE: To investigate the prognostic value of ADNEX Magnetic Resonance Imaging Scoring in the preoperative management of adnexal masses. STUDY DESIGN: We performed a retrospective study on patients who underwent surgery for an adnexal mass, with prior exploration by Magnetic Resonance Imaging (MRI), at the Gynecology Department of the Poissy Teaching Hospital between May 2012 and August 2014. MRI data were retrospectively read by radiologists, without knowledge of the histology, and classified according to the criteria of the ADNEX MR score. The radiological presumption of benign or malignant mass was compared with the final histological diagnosis. We calculated the sensitivity, specificity, positive and negative likelihood ratios and ROC curve of the ADNEX MR score with their 95% confidence intervals (95%CI). RESULTS: One-hundred-and-forty-eight patients were included in the study of which 24 had malignant or borderline ovarian tumors. The proportion of malignant or borderline ovarian tumors in each class of the ADNEX MR score in our study was: ADNEX I: 0% (95%CI, 0-8); ADNEX II: 1.7% (95%CI, 0.04-8.9); ADNEX III: 7.7% (95%CI, 0.2-36); ADNEX IV: 57.1% (95%CI, 34.2-78.8) and ADNEX V: 100% (95%CI, 69.2-100). Thus, for an ADNEX MR score greater than or equal to 4, the sensitivity was 91.7% (95%CI, 73-99) and the specificity 92.7% (95%CI, 86.7-96.6) for the diagnosis of a malignant or borderline ovarian tumor. The area under the ROC curve was 0.92 (95% CI%, 0.86-0.98). CONCLUSIONS: MRI, coupled with the use of the ADNEX MR scoring system, can accurately classify adnexal masses into low-risk (ADNEX MR score <4) or high-risk (ADNEX MR score ≥4) group, thereby allowing for appropriate preoperative counseling and planning for surgery.
OBJECTIVE: To investigate the prognostic value of ADNEX Magnetic Resonance Imaging Scoring in the preoperative management of adnexal masses. STUDY DESIGN: We performed a retrospective study on patients who underwent surgery for an adnexal mass, with prior exploration by Magnetic Resonance Imaging (MRI), at the Gynecology Department of the Poissy Teaching Hospital between May 2012 and August 2014. MRI data were retrospectively read by radiologists, without knowledge of the histology, and classified according to the criteria of the ADNEX MR score. The radiological presumption of benign or malignant mass was compared with the final histological diagnosis. We calculated the sensitivity, specificity, positive and negative likelihood ratios and ROC curve of the ADNEX MR score with their 95% confidence intervals (95%CI). RESULTS: One-hundred-and-forty-eight patients were included in the study of which 24 had malignant or borderline ovarian tumors. The proportion of malignant or borderline ovarian tumors in each class of the ADNEX MR score in our study was: ADNEX I: 0% (95%CI, 0-8); ADNEX II: 1.7% (95%CI, 0.04-8.9); ADNEX III: 7.7% (95%CI, 0.2-36); ADNEX IV: 57.1% (95%CI, 34.2-78.8) and ADNEX V: 100% (95%CI, 69.2-100). Thus, for an ADNEX MR score greater than or equal to 4, the sensitivity was 91.7% (95%CI, 73-99) and the specificity 92.7% (95%CI, 86.7-96.6) for the diagnosis of a malignant or borderline ovarian tumor. The area under the ROC curve was 0.92 (95% CI%, 0.86-0.98). CONCLUSIONS: MRI, coupled with the use of the ADNEX MR scoring system, can accurately classify adnexal masses into low-risk (ADNEX MR score <4) or high-risk (ADNEX MR score ≥4) group, thereby allowing for appropriate preoperative counseling and planning for surgery.
Authors: Elizabeth A Sadowski; Isabelle Thomassin-Naggara; Andrea Rockall; Katherine E Maturen; Rosemarie Forstner; Priyanka Jha; Stephanie Nougaret; Evan S Siegelman; Caroline Reinhold Journal: Radiology Date: 2022-01-18 Impact factor: 11.105
Authors: Isabelle Thomassin-Naggara; Edouard Poncelet; Aurelie Jalaguier-Coudray; Adalgisa Guerra; Laure S Fournier; Sanja Stojanovic; Ingrid Millet; Nishat Bharwani; Valerie Juhan; Teresa M Cunha; Gabriele Masselli; Corinne Balleyguier; Caroline Malhaire; Nicolas F Perrot; Elizabeth A Sadowski; Marc Bazot; Patrice Taourel; Raphaël Porcher; Emile Darai; Caroline Reinhold; Andrea G Rockall Journal: JAMA Netw Open Date: 2020-01-03